Related Jobs
-
Senior Clinical Research Associate
Job Type: Permanent
Salary: € 30000.00 per annum
Location: Croatia -
CRA II / Snr CRA
Job Type: Permanent
Salary: £ 42000.00 per annum
Location: Netherlands - Amsterdam
Forest: Ceftaroline achieved primary endpoint
29 Oct 2008
Clinical Research
Forest Laboratories has said that ceftaroline monotherapy has achieved the primary endpoint in a phase-three clinical trial.
Ceftaroline, a novel cephalosporin agent, demonstrated cure rates which were not more than ten per cent lower than comparitor regimens in the treatment of complicated skin and skin structure infections (cSSSIs).
The treatment was also well-tolerated during the trial, the company stated.
Ralph Corey, director of infectious diseases at the Duke Clinical Research Institute, said: "These new data add to the growing scientific evidence that support ceftaroline as a potential novel treatment for cSSSIs, including those caused by MRSA."
He added that the results are "important" because there are a growing number of infections, many of which are difficult to treat.
Meanwhile, Forest Laboratories has announced it has entered into a collaboration agreement with Phenomix to develop and commercialise dutogliptin in North America.
Under the terms of the deal, Forest is making an upfront payment of $75 million (£47 million) to Phenomix and the firms will equally share profits and expenses linked to the product.
